Urea Cycle News and Research

RSS
Urea cycle disorders are congenital diseases that are caused by a dysfunctional urea cycle. The genetics and biochemistry of these disorders have been extensively studied. They are the result of a deficiency of one of the six enzymes that catalyze the various biochemical reactions in the urea cycle which converts ammonia to urea for removal via urine.
Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Polyamine-deficient diets effective as pain relief treatment for chronic and acute pain

Polyamine-deficient diets effective as pain relief treatment for chronic and acute pain

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Hyperion acquires worldwide rights to Ucyclyd's Ravicti

Hyperion acquires worldwide rights to Ucyclyd's Ravicti

ISCO discovers novel technology to produce pure hepatocyte population

ISCO discovers novel technology to produce pure hepatocyte population

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

ISCO completes first series of hepatocytes preclinical testing

ISCO completes first series of hepatocytes preclinical testing

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders

Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Drug sodium phenylbutyrate could improve the memory of those with Alzheimer's disease

Drug sodium phenylbutyrate could improve the memory of those with Alzheimer's disease

New hope for leptin as a solution to obesity

New hope for leptin as a solution to obesity

Watermelon provides Viagra-like effects

Watermelon provides Viagra-like effects